BackgroundThe UK introduced the 7-valent pneumococcal conjugate vaccine (PCV7) into the national vaccination program in September 2006. Previous modelling assumed that the likely impact of PCV7 on inv
Serotype cases and incidence of invasive pneumococcal disease after introduction of pneumococcal conjugate vaccines in BC compared with the baseline average of 2002–2003.
